Citius Oncology, Inc.
CTORNasdaqCIK 1851484HealthcareFiscal year ends Sep 30
Latest reported revenue, Q3 FY2026$1.5mRevenue, Q3 FY2026, three months to 2026-06-30$1.5m. XBRL concept
us-gaap:Revenues. 10-Q filed 2026-08-14, accession 0001213900-26-090184.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 14, 2026.Latest quarter: Q3 FY2026
Three months to Jun 30, 2026, against the same quarter a year earlier.
- Revenue$1.5mRevenue, Q3 FY2026, three months to 2026-06-30$1.5m. XBRL concept
us-gaap:Revenues. 10-Q filed 2026-08-14, accession 0001213900-26-090184.Report this figureNo year-earlier figure to compare - Gross margin67.1%Gross margin, Q3 FY2026, three months to 2026-06-30. gross profit / revenueGross profit: $1.0m. XBRL concept
us-gaap:GrossProfit. 10-Q filed 2026-08-14, accession 0001213900-26-090184.Revenue: $1.5m. XBRL conceptus-gaap:Revenues. 10-Q filed 2026-08-14, accession 0001213900-26-090184.Report this figureNo year-earlier figure to compare - Operating margin−583.5%Operating margin, Q3 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$8.7m. XBRL concept
us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-14, accession 0001213900-26-090184.Revenue: $1.5m. XBRL conceptus-gaap:Revenues. 10-Q filed 2026-08-14, accession 0001213900-26-090184.Report this figureNo year-earlier figure to compare - Net margin−597.4%Net margin, Q3 FY2026, three months to 2026-06-30. net income / revenueNet income: −$8.9m. XBRL concept
us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001213900-26-090184.Revenue: $1.5m. XBRL conceptus-gaap:Revenues. 10-Q filed 2026-08-14, accession 0001213900-26-090184.Report this figureNo year-earlier figure to compare - Diluted EPS−$0.08Diluted EPS, Q3 FY2026, three months to 2026-06-30−$0.08 per share. XBRL concept
us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-14, accession 0001213900-26-090184.Report this figure+0.0% on a year earlier - Free cash flownot reported (Capital expenditure not reported)No year-earlier figure to compare
Last eight quarters
Full statements| Line item | Unit | Q4 FY20242024-09-30 | Q1 FY20252024-12-31 | Q2 FY20252025-03-31 | Q3 FY20252025-06-30 | Q4 FY20252025-09-30 | Q1 FY20262025-12-31 | Q2 FY20262026-03-31 | Q3 FY20262026-06-30 | Shape over the periods |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $k | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | 3,944Revenue, Q1 FY2026, three months to 2025-12-31$3.9m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-02-13, accession 0001213900-26-015877.Report this figure | 1,667Revenue, Q2 FY2026, three months to 2026-03-31$1.7m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-15, accession 0001213900-26-057841.Report this figure | 1,494Revenue, Q3 FY2026, three months to 2026-06-30$1.5m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-14, accession 0001213900-26-090184.Report this figure | |
| Gross margin | % | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | 80.0%Gross margin, Q1 FY2026, three months to 2025-12-31. gross profit / revenueGross profit: $3.2m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-02-13, accession 0001213900-26-015877.Revenue: $3.9m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-02-13, accession 0001213900-26-015877.Report this figure | 80.3%Gross margin, Q2 FY2026, three months to 2026-03-31. gross profit / revenueGross profit: $1.3m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-05-15, accession 0001213900-26-057841.Revenue: $1.7m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-15, accession 0001213900-26-057841.Report this figure | 67.1%Gross margin, Q3 FY2026, three months to 2026-06-30. gross profit / revenueGross profit: $1.0m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-14, accession 0001213900-26-090184.Revenue: $1.5m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-14, accession 0001213900-26-090184.Report this figure | |
| Operating margin | % | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | (133.2%)Operating margin, Q1 FY2026, three months to 2025-12-31. operating income / revenueOperating income: −$5.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-02-13, accession 0001213900-26-015877.Revenue: $3.9m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-02-13, accession 0001213900-26-015877.Report this figure | (1716.2%)Operating margin, Q2 FY2026, three months to 2026-03-31. operating income / revenueOperating income: −$28.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-15, accession 0001213900-26-057841.Revenue: $1.7m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-15, accession 0001213900-26-057841.Report this figure | (583.5%)Operating margin, Q3 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$8.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-14, accession 0001213900-26-090184.Revenue: $1.5m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-14, accession 0001213900-26-090184.Report this figure | |
| Net margin | % | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | (140.3%)Net margin, Q1 FY2026, three months to 2025-12-31. net income / revenueNet income: −$5.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001213900-26-090184.Revenue: $3.9m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-02-13, accession 0001213900-26-015877.Report this figure | (1596.0%)Net margin, Q2 FY2026, three months to 2026-03-31. net income / revenueNet income: −$26.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001213900-26-090184.Revenue: $1.7m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-15, accession 0001213900-26-057841.Report this figure | (597.4%)Net margin, Q3 FY2026, three months to 2026-06-30. net income / revenueNet income: −$8.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001213900-26-090184.Revenue: $1.5m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-14, accession 0001213900-26-090184.Report this figure | |
| Diluted EPS | $ per share | not reported (Diluted EPS not reported) | (0.09)Diluted EPS, Q1 FY2025, three months to 2024-12-31−$0.09 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-02-13, accession 0001213900-26-015877.Report this figure | (0.11)Diluted EPS, Q2 FY2025, three months to 2025-03-31−$0.11 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-15, accession 0001213900-26-057841.Report this figure | (0.08)Diluted EPS, Q3 FY2025, three months to 2025-06-30−$0.08 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-14, accession 0001213900-26-090184.Report this figure | not reported (Diluted EPS not reported) | (0.06)Diluted EPS, Q1 FY2026, three months to 2025-12-31−$0.06 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-02-13, accession 0001213900-26-015877.Report this figure | (0.27)Diluted EPS, Q2 FY2026, three months to 2026-03-31−$0.27 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-15, accession 0001213900-26-057841.Report this figure | (0.08)Diluted EPS, Q3 FY2026, three months to 2026-06-30−$0.08 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-14, accession 0001213900-26-090184.Report this figure | |
| Free cash flow | $k | not reported (Operating cash flow and Capital expenditure not reported) | not reported (Operating cash flow and Capital expenditure not reported) | not reported (Operating cash flow and Capital expenditure not reported) | not reported (Operating cash flow and Capital expenditure not reported) | not reported (Operating cash flow and Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) |
Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.
Last five fiscal years
| Line item | Unit | FY20222022-12-31 | FY20232023-09-30 | FY20232023-12-31 | FY20242024-09-30 | FY20252025-09-30 | Shape over the periods |
|---|---|---|---|---|---|---|---|
| Revenue | $ | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | |
| Gross margin | % | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | |
| Operating margin | % | not reported (Revenue not reported) | not reported (Operating income and Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | |
| Net margin | % | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | |
| Diluted EPS | $ per share | 0.12Diluted EPS, FY2022, twelve months to 2022-12-31$0.12 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-04-16, accession 0001493152-24-014850.Report this figure | (0.19)Diluted EPS, FY2023, twelve months to 2023-09-30−$0.19 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-12-27, accession 0001213900-24-113150.Report this figure | 0.27Diluted EPS, FY2023, twelve months to 2023-12-31$0.27 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-04-16, accession 0001493152-24-014850.Report this figure | (0.31)Diluted EPS, FY2024, twelve months to 2024-09-30−$0.31 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-12-23, accession 0001213900-25-125331.Report this figure | (0.34)Diluted EPS, FY2025, twelve months to 2025-09-30−$0.34 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-12-23, accession 0001213900-25-125331.Report this figure | |
| Free cash flow | $ | not reported (Capital expenditure not reported) | not reported (Operating cash flow and Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) |
Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.
Insider purchases and sales
All insider transactionsThe last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.
No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.
No open-market purchases or sales by insiders are in coverage for this company.
Funds that report holding it
All fundsFrom each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.
| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 2026-06-30 | $5.7m | 8,705,589 | Reduced−483,266 | |
| BANK OF AMERICA CORP /DE/ | 2026-06-30 | $2.5m | 3,835,160 | Unchanged | |
| VANGUARD CAPITAL MANAGEMENT LLC | 2026-06-30 | $355.1k | 546,325 | Added+11,501 | |
| UBS Group AG | 2026-06-30 | $217.5k | 334,619 | Added+297,779 | |
| GEODE CAPITAL MANAGEMENT, LLC | 2026-06-30 | $159.5k | 245,407 | Reduced−19,326 | |
| VANGUARD FIDUCIARY TRUST CO | 2026-06-30 | $79.2k | 121,910 | Unchanged | |
| IFP Advisors, Inc | 2026-06-30 | $69.8k | 107,424 | Unchanged | |
| CITADEL ADVISORS LLC | 2026-06-30 | $58.9k | 90,586 | New+90,586 | |
| NORTHERN TRUST CORP | 2026-06-30 | $29.7k | 45,746 | Unchanged | |
| STATE STREET CORP | 2026-06-30 | $27.9k | 42,900 | Unchanged |
Recent filings
All 266 filingsReports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-2316:10 ET | 8-K | 8.01 Other events | 0001213900-26-112109 |
| 2026-09-2916:30 ET | 8-K | 5.07 Shareholder vote results | 0001213900-26-104694 |
| 2026-08-2609:00 ET | DEF 14A | Proxy statementPeriod 2026-09-29 | 0001213900-26-093757 |
| 2026-08-1416:35 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001213900-26-090184 |
| 2026-08-1416:35 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001213900-26-090182 |
| 2026-08-1208:30 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001213900-26-088068 |
| 2026-08-0509:28 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-085434 |
| 2026-06-0416:30 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001213900-26-065310 |
| 2026-06-0116:30 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-063530 |
| 2026-05-1516:44 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001213900-26-057883 |
Latest annual report
Form 10-K for the fiscal year ended Sep 30, 2025Filed Dec 23, 2025. Its page lists the documents and the extracted sections, such as Business and Risk factors.
Forecast league
Q4 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter
About the filer
- CIK
- 1851484
- Tickers
- CTOR
- Exchange
- Nasdaq
- SIC code
- 2834 Pharmaceutical Preparations
- Sector
- Healthcare
- Fiscal year ends
- Sep 30
- Incorporated in
- DE
- Filer category
- <br>Emerging growth company
- Former names
- TenX Keane Acquisition (to 2024-08-05)
Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 26, 2026, 16:06 ET. Listed shows no prices and gives no investment advice.